Neuphoria Therapeutics Inc. Increase Decrease In Contingent Consideration Asset Liability
Neuphoria Therapeutics Inc. (NEUP) reported Increase Decrease In Contingent Consideration Asset Liability of AUD 988.18 thousand for the 12-month period ending 2023-06-30, per its 20-F filed 2023-10-18.
Discontinued › Cash Flow › Operating Activities
ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability · last filed 2023-10-18
| Period end | Increase Decrease In Contingent Consideration Asset Liability 12 month |
|---|---|
| 2023-06-30 | 988.18K AUD 20-F · filed 2023-10-18 |
| 2022-06-30 | 936.35K AUD 20-F · filed 2023-10-18 |
| 2021-06-30 | -3.21M AUD 20-F · filed 2022-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |